Full-Time

Principal Data Scientist

AbbVie

AbbVie

10,001+ employees

Global biopharmaceutical company developing medicines

Compensation Overview

$124.5k - $236.5k/yr

+ Long-term incentive program

Florham Park, NJ, USA

Hybrid

Bachelor's, Master's, PhD

Category
Data & Analytics (1)
Required Skills
LLM
Scikit-learn
Python
Data Science
TensorFlow
R
Neural Networks
PyTorch
Apache Spark
SQL
Machine Learning
MLflow
Data Engineering
A/B Testing
Version Control
Pandas
REST APIs
NumPy
Databricks
Reinforcement Learning

Get referred to AbbVie

See people who can refer or advise you

Requirements
  • A bachelor's degree in Statistics, Mathematics, Computer Science, Engineering, or another quantitative discipline is required.
  • At least 8 years of experience in data science, machine learning, or advanced analytics, including delivery of production-quality models and solutions, is required.
  • At least 4 years of experience in omnichannel analytics is required, including journey analysis, touchpoint measurement, engagement optimization, or next-best-action modeling.
  • At least 4 years of experience measuring commercial effectiveness and business impact using promotional response analysis, closed-loop measurement, A/B testing, and quasi-experimental techniques is required.
  • Strong proficiency in Python and/or R and strong SQL skills are required, including hands-on Python experience with pandas, NumPy, scikit-learn, and PySpark.
  • Hands-on experience with deep learning frameworks such as PyTorch or TensorFlow is required for sequential, temporal, or recommendation use cases.
  • Experience working with product owners, business stakeholders, and cross-functional teams to translate requirements into technical solutions is required.
  • Experience productionizing AI/ML solutions in cloud environments, including deployment, monitoring, and lifecycle management, is required.
Responsibilities
  • Lead a portfolio of advanced analytics capabilities across customer understanding, engagement planning, decision support, and measurement.
  • Translate product requirements and business goals into scalable technical solutions, including model design, feature engineering, validation, and deployment.
  • Lead the design and development of predictive and inferential models using complex, multi-source data to generate actionable insights on customer behavior, engagement opportunities, and business performance.
  • Design analytics approaches that evaluate cross-channel engagement patterns, interaction effects, and temporal dynamics to inform coordinated customer strategies.
  • Own measurement methodologies for effectiveness, incrementality, and business impact using experimental and observational methods.
  • Partner with BTS, Digital Lab, engineering, and platform teams to build scalable, production-ready analytics and AI/ML solutions.
  • Establish best practices in model development, including code quality, documentation, reproducibility, peer review, version control, and methodological rigor.
  • Synthesize complex technical findings into clear, actionable insights and recommendations for non-technical stakeholders.
  • Partner with engineering and platform teams to productionize AI/ML solutions, including deployment, monitoring, and lifecycle management.
  • Stay current with advances in applied machine learning, causal inference, and pharmaceutical analytics, and identify and pilot emerging methods.
  • Provide technical mentorship and hands-on guidance to junior and mid-level data scientists.
  • Lead technical workstreams with external analytics vendors and partners, including oversight of deliverable quality and methodology validation.
Desired Qualifications
  • A master's or PhD in a quantitative field is strongly preferred.
  • At least 5 years of experience in pharmaceutical, biotech, healthcare, or life sciences commercial analytics is highly preferred.
  • Experience with advanced machine learning and optimization methods, including reinforcement learning, multi-armed bandits, transformers, and other deep learning approaches for sequential, recommendation, or next-best-action use cases is preferred.
  • Familiarity with pharmaceutical data sources such as IQVIA, Symphony Health, APLD, or similar prescription, claims, and engagement datasets is preferred.
  • Experience working in agile product development environments is preferred.
  • Exposure to cloud machine learning platforms and MLOps tools such as Azure ML, Databricks, and MLflow is preferred.
  • Experience presenting analytical methods and findings to senior or executive audiences is preferred.
  • Exposure to modern AI engineering approaches, including large language model-based workflows, orchestration frameworks, or agentic AI patterns, is preferred.
  • Experience integrating AI/ML solutions using APIs, pipelines, or orchestration tools is preferred.

AbbVie is a global biopharmaceutical company that develops and sells medicines to treat serious health conditions. Its portfolio spans immunology, oncology, virology, neuroscience, and aesthetics, with products designed to modulate the immune system, target disease pathways, or support medical aesthetics. AbbVie compounds its products through a heavy emphasis on research and development, investing billions to build a steady pipeline of new therapies. Its medicines are brought to market by selling to healthcare providers, hospitals, and clinics, and in some cases directly to patients via prescriptions. The company differentiates itself through a wide, globally distributed product line, substantial R&D investment, and a commitment to sustainability and patient care, including science-based targets. AbbVie’s goal is to improve patient outcomes by delivering effective treatments for unmet medical needs while pursuing long-term, responsible growth across healthcare markets.

Company Size

10,001+

Company Stage

IPO

Headquarters

North Chicago, Illinois

Founded

1888

Get referred to AbbVie

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • AbbVie raised 2026 revenue guidance to $67.6 billion after Q2 2026.
  • FDA review of SKYRIZI Crohn's subcutaneous induction targets a late-2026 approval.
  • WCLC 2026 data showed ABBV-1480 90% response in squamous NSCLC.

What critics are saying

  • HUMIRA revenue fell 36.1% in Q2 2026 as biosimilars keep taking share.
  • The Apogee deal cuts 2026 EPS by $0.14 and adds debt financing.
  • Epcoritamab missed the July 23, 2026 DLBCL endpoint, threatening future B-cell franchise growth.

What makes AbbVie unique

  • SKYRIZI and RINVOQ drove $8.8 billion of Q2 2026 immunology revenue.
  • Botox Cosmetic and Juvederm generated $973 million in Q2 2026 aesthetics sales.
  • Apogee purchase adds late-stage IL-13 and TSLP programs for eczema and asthma.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Flexible Work Hours

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

3%

1 year growth

3%

2 year growth

3%
Yahoo Finance
Aug 21st, 2026
AbbVie stock moves independently from market with 0.22 correlation driven by immunology drugs

AbbVie stock shows a correlation of just 0.22 to the S&P 500 over five years, meaning most of its movements stem from company-specific factors rather than broader market trends. The pharmaceutical firm's immunology segment generated nearly $8.8 billion of its $17 billion in second-quarter 2026 revenue, led by SKYRIZI at $5.5 billion and RINVOQ at over $2.5 billion. These treatments for chronic diseases have prices negotiated with payers, not consumers. AbbVie has delivered an annualised return of 21.5% with 23.5% volatility over five years, compared to the S&P 500's 12.9% return at 17.2% volatility. The company converts 28.3% of revenue into free cash flow, nearly double the S&P 500 median of 14.5%.

Grafa
Aug 21st, 2026
AbbVie reports 90% response in lung cancer study.

AbbVie reports 90% response in lung cancer study. * AbbVie reported a 90% objective response rate for ABBV-1480 plus platinum chemotherapy in squamous advanced NSCLC at the selected 10 mg/kg dose. * The same dose produced a 75.9% response rate in non-squamous disease and was selected as the recommended Phase 3 dose. * AbbVie will also present data for Temab-A and ABBV-706 across NSCLC and small cell lung cancer at the 2026 World Conference on Lung Cancer. AbbVie (NYSE:ABBV) reported Phase 1b lung cancer data showing objective response rates of 90% in squamous and 75.9% in non-squamous advanced NSCLC with ABBV-1480 plus platinum chemotherapy. At the 10 mg/kg dose, 27 of 30 patients with squamous disease and 22 of 29 with non-squamous disease achieved objective responses, according to the company. AbbVie said the findings support further evaluation of ABBV-1480 in advanced NSCLC and selected the 10 mg/kg regimen as the recommended Phase 3 dose. The company will present additional clinical results for telisotuzumab adizutecan, or Temab-A, in first-line non-squamous and EGFR-mutated NSCLC at the 2026 World Conference on Lung Cancer. AbbVie will also report ABBV-706 data in relapsed or refractory small cell lung cancer, including new safety analyses covering 240 patients. The company's conference presentations include real-world evidence evaluating SEZ6 as a potential therapeutic target in small cell lung cancer. The updates form part of AbbVie's clinical development program across non-small cell and small cell lung cancers, with several investigational therapies being evaluated across different treatment settings. Frequently asked questions. ABBV signals

Yahoo Finance
Aug 19th, 2026
AbbVie stock eyes breakout as Skyrizi dosing decision could unlock $24.5B revenue growth

AbbVie stock has returned 24.5% over the past three months, trading near its 52-week high. The pharmaceutical company's growth hinges on a pending regulatory decision for SKYRIZI, an immunology treatment that generates nearly a third of guided revenue. SKYRIZI sold $5.5 billion in Q2 2026, up 24% operationally. AbbVie guides the drug to $21.7 billion for 2026 against total company revenue of approximately $67.6 billion. The company has raised its 2026 guidance twice by $600 million combined. A subcutaneous induction option for Crohn's disease awaits regulatory approval this fall. Management expects the new dosing method to meaningfully accelerate SKYRIZI sales, though the commercial impact won't materialise until early 2027 due to contract timelines. Clinical trial results showed endoscopic response and remission rates 25 points above placebo.

BBC
Aug 19th, 2026
UK's Smith+Nephew CFO John Rogers to step down for external role.

UK's Smith+Nephew CFO John Rogers to step down for external role. August 19, 2026 The departure follows Smith+Nephew's decision weeks ago to cut its annual revenue growth forecast after second-quarter sales missed expectations due to weak U.S. knee and hip implant demand and pressure on skin substitute pricing International News via Reuters: Smith+Nephew said on Wednesday its finance chief John Rogers would step down at the end of September to take up an external position in the United States, ending his roughly two-and-a-half-year tenure with the medical products company. Here are some more details: - The departure follows Smith+Nephew's decision weeks ago to cut its annual revenue growth forecast after second-quarter sales missed expectations due to weak U.S. knee and hip implant demand and pressure on skin substitute pricing. - Smith+Nephew said it had appointed Senior Vice President Finance and Group Controller Pierre Palassian as interim chief financial officer until a permanent replacement was appointed. - Palassian, who joined Smith+Nephew in 2017, previously held senior roles at AbbVie and Abbott Laboratories. - Rogers, who took up the CFO role in early 2024, had relocated to the United States in 2025 for operational efficiencies. - Shares in the FTSE 100 company have gained nearly 14% during Rogers' tenure as CFO. - Smith+Nephew said Rogers would receive no severance payment, and that his outstanding incentive and share awards would lapse on September 30 under leaver rules. Reporting by Neeshita Beura in Bengaluru; Editing by Subhranshu Sahu - Advertisement - August 19, 2026 - Advertisement -

Yahoo Finance
Aug 15th, 2026
AbbVie shows strong cash flow margin of 34.8% but faces tepid revenue growth

AbbVie, the biopharmaceutical company spun off from Abbott Laboratories in 2013, has risen 9.7% to $249.64 per share over the past six months. The company generates $64.39 billion in revenue over the past 12 months, benefiting from significant economies of scale in its operations. AbbVie's free cash flow margin averaged 34.8% over the last five years, amongst the best in the healthcare sector. This strong cash generation enables reinvestment and capital returns to investors. However, the company's five-year annualised revenue growth of 3.7% remains tepid compared to sector peers. Despite this weakness, AbbVie's shares trade at 16.3 times forward price-to-earnings ratio. The company develops and markets medications for autoimmune diseases, cancer, neurological disorders, and other complex health conditions.